Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden, Moshe Elkabets (Herausgeber)

Buch | Softcover

XX, 242 Seiten

2019 | 1. Softcover reprint of the original 1st ed. 2018
Springer International Publishing (Verlag)
978-3-030-09817-9 (ISBN)

Artikel merken

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.

Erscheinungsdatum	18.02.2019
Reihe/Serie	Resistance to Targeted Anti-Cancer Therapeutics
Zusatzinfo	XX, 242 p. 22 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	155 x 235 mm
Gewicht	409 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Themenwelt	Medizin / Pharmazie ► Studium
Schlagworte	Anti-cancer • Kinases • resistance • therapeutics • tyrosine
ISBN-10	3-030-09817-6 / 3030098176
ISBN-13	978-3-030-09817-9 / 9783030098179
Zustand	Neuware